Chronic Myeloid Leukemia Drugs Market | Size, Share, Growth

Chronic Myeloid Leukemia Drugs Market Research Report

Published: 2025 - January

Report Code: VMR-7986

Region: Global

Request Sample

Customization

Ask an Expert

Enquire Enquire Before Buying

Chronic Myeloid Leukemia (CML) Market Analysis

The Chronic Myeloid Leukemia (CML) Market encompasses the research, development, and commercialization of therapies targeting this rare hematologic malignancy characterized by the overproduction of abnormal white blood cells due to a genetic mutation (BCR-ABL fusion gene). This market includes innovative drugs, diagnostics, and advanced treatment approaches that address all stages of the disease, offering precision-driven solutions for improved patient outcomes.

Disruptive Impact and Opportunities:

Emerging drugs such as HQP1351, TERN-701, Navtemadlin, and Ropeginterferon alfa-2b are poised to redefine therapeutic pathways with novel mechanisms of action. Advancements in oral formulations, like Tyrosine Kinase Inhibitors (TKIs), enable easier disease management for patients. Next-generation therapies, such as SCEMBLIX (asciminib), focus on improved specificity and reduced side effects, ensuring safer treatment regimens. The CML market is projected to grow significantly, driven by an expanding patient pool, increased R&D investments, and robust drug pipelines.

Chronic Myeloid Leukemia (CML) Market Segmentation - Emerging Drugs

HQP1351
TERN-701
Navtemadlin
Ropeginterferon alfa-2b

Chronic Myeloid Leukemia (CML) Market Segmentation - Marketed Drugs

SCEMBLIX (asciminib)
ICLUSIG (ponatinib)
TASIGNA (nilotinib)
BOSULIF (bosutinib)
SPRYCEL (dasatinib)

Key Companies:

Kartos Therapeutics
AOP Orphan Pharmaceuticals
Biokine Therapeutics
Incyte Corporation
Sana Biotechnology
Novartis
Nerviano Medical Sciences
Sun Pharma Advanced Research Company

Chronic Myeloid Leukemia (CML) Market Segmentation - By Type

· Tyrosine Kinase Inhibitors (TKIs)

First-Generation TKIs
Second-Generation TKIs
Third-Generation TKIs

· Chemotherapy Drugs

· Immunotherapy Drugs

Others

Chronic Myeloid Leukemia (CML) Market Segmentation - By Administration Type

· Oral

· Intravenous

· Subcutaneous

· Others

What’s in It for You?

Comprehensive insights into emerging drugs and pipeline opportunities.
Competitive benchmarking of leading players and their strategies.
Analysis of market trends, growth drivers, and key challenges.
Strategic guidance for investment decisions and portfolio expansion.

Chronic Myeloid Leukemia Market Analysis (Market Size & CAGR, Epidemiology, Marketed Therapies, Emerging Drugs, Clinical Trials, Key Approvals & Anticipated Loss of Exclusivity, Opportunities, Unmet Needs, Company Profiles)

1. Chronic Myeloid Leukemia Market - Executive Summary

1.1. Introduction

1.2. Objectives

1.3. Key Findings

1.3.1. Market Size 2025 & 2030: By Key Country (10MM)

1.3.2. Global Market Size 2025 & 2030: By Key Segment

1.3.3. Key Investments & Startup Analysis

1.4. Research Methodology

2. Understanding the Disease

2.1. Disease Overview

2.2. Classification

2.3. Signs and Symptoms

2.4. Risk Factors

2.5. Causes

2.6. Disease Biology & Digital Innovations

2.7. Stages & Staging System

2.8. Diagnostic Algorithm

2.9. Current Treatment Practices & Algorithm

2.10. Current Standard of Care and Treatment Gaps

2.11. Patient Demographics and Treatment Pathways

3. Guidelines

4. Unmet Needs

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 10MM

5.3. Epidemiology Scenario: 10MM

5.4. U.S. Epidemiology Scenario

5.5. EU-5 Epidemiology

5.5.1. U.K. Epidemiology Scenario

5.5.2. Germany Epidemiology Scenario

5.5.3. France Epidemiology Scenario

5.5.4. Italy Epidemiology Scenario

5.5.5. Spain Epidemiology Scenario

5.6. Japan Epidemiology Scenario

5.7. China Epidemiology Scenario

5.8. Australia Epidemiology Scenario

5.9. India Epidemiology Scenario

6. Real-world Data & Real-world Evidence

7. Drug Development Landscape

7.1. Existing Key Drug Candidate Profiles/ Marketed Therapies

7.1.1. SCEMBLIX (asciminib)

7.1.1.1. Product Description

7.1.1.2. Regulatory Milestones

7.1.1.3. Other Developmental Activities

7.1.1.4. Pivotal Clinical Trials

7.1.1.5. Ongoing Current Pipeline Activity

7.1.2. ICLUSIG (ponatinib)

7.1.2.1. Product Description

7.1.2.2. Regulatory Milestones

7.1.2.3. Other Developmental Activities

7.1.2.4. Pivotal Clinical Trials

7.1.2.5. Ongoing Current Pipeline Activity

7.1.3. TASIGNA (nilotinib)

7.1.3.1. Product Description

7.1.3.2. Regulatory Milestones

7.1.3.3. Other Developmental Activities

7.1.3.4. Pivotal Clinical Trials

7.1.3.5. Ongoing Current Pipeline Activity

7.1.4. BOSULIF (bosutinib)

7.1.4.1. Product Description

7.1.4.2. Regulatory Milestones

7.1.4.3. Other Developmental Activities

7.1.4.4. Pivotal Clinical Trials

7.1.4.5. Ongoing Current Pipeline Activity

7.2. Competitive Analysis and Differentiation

7.3. Overview of Similar/Competing Drugs in Clinical Trials

7.4. Future Trends and Emerging Drugs

7.4.1. HQP1351

7.4.1.1. Product Description

7.4.1.2. Clinical Development

7.4.1.3. Safety and Efficacy

7.4.2. TERN-701

7.4.2.1. Product Description

7.4.2.2. Clinical Development

7.4.2.3. Safety and Efficacy

7.4.3. Navtemadlin

7.4.3.1. Product Description

7.4.3.2. Clinical Development

7.4.3.3. Safety and Efficacy

8. Regulatory Strategy and Potential Challenges

8.1. Regulatory Pathways in Key Markets

8.2. Anticipated Regulatory Hurdles and Mitigation Strategies

8.3. Case Studies in Oncology Drug Regulation

8.4. Impact of Potential Changes to Regulatory Framework

9. Commercial Landscape

9.1. Market Size & Growth Rates

9.2. Key Approvals & Anticipated Loss of Exclusivity

9.3. PESTLE & Porter’s Five Forces Analysis

9.4. Market Shares, Positioning/Ranking

9.5. Market Drivers

9.6. Identification of Threats

9.7. Digital Evolution in Commercialization

10. Market Segmentation

10.1. Market by Therapy Type

10.1.1. Chemotherapy

10.1.2. Targeted Therapy

10.1.3. Others

11. Pricing, Reimbursement, and Access

11.1. Competitive Pricing Analysis

11.2. Reimbursement Landscape and Challenges

11.3. Strategies for Market Access and Equity

11.4. Patient Spending/Expenditure Analysis

12. Future Trends, Disruptions, and Opportunities

12.1. Analysis of Emerging Trends

12.2. Technological Impact

12.3. Impact of Potential Market Disruptors

12.4. Opportunities for Future Development and Expansion

12.5. Considerations for Investment Opportunities

13. Global Market Dynamics

13.1. Regional Regulatory Disparities

13.2. Cross-Border Partnership Strategies

13.3. Global Supply Chain Dynamics

13.4. Case Studies: Success and Failure in Global Markets

13.5. Strategies for Global Expansion and Localization

14. Company Profiles

14.1. Kartos Therapeutics

14.2. AOP Orphan Pharmaceuticals

14.3. Biokine Therapeutics

14.4. Incyte Corporation

14.5. Sana Biotechnology

14.6. Novartis

14.7. Nerviano Medical Sciences

14.8. Sun Pharma Advanced Research Company

14.9. Bristol-Myers Squibb

14.10. Pfizer

Download Sample

Full Name *

Job Title *

Company *

Email *

Phone *

Country *

Message

↻

The field with (*) is required.

Choose License Type

Excel Data Pack

2500

Single User

4250

Multi User

5250

Corporate User

6900